Traumatic brain injury (TBI) is one of the leading causes of death among young people, and is increasingly prevalent in the aging population. Survivors of TBI face a spectrum of outcomes from short-term non-incapacitating injuries to long-lasting serious and deteriorating sequelae. TBI is a highly complex condition to treat; many variables can account for the observed heterogeneity in patient outcome. The limited success of neuroprotection strategies in the clinic has led to a new emphasis on neurorestorative approaches. In TBI, it is well recognized clinically that patients with similar lesions, age, and health status often display differences in recovery of function after injury. Despite this heterogeneity of outcomes in TBI, restorative treatment has remained generic. There is now a new emphasis on developing a personalized medicine approach in TBI, and this will require an improved understanding of how genetics impacts on long-term outcomes. Studies in animal model systems indicate clearly that the genetic background plays a role in determining the extent of recovery following an insult. A candidate gene approach in human studies has led to the identification of factors that can influence recovery. Here we review studies of the genetic basis for individual differences in functional recovery in the CNS in animals and man. The application of in vitro modeling with human cells and organoid cultures, along with whole-organism studies, will help to identify genes and networks that account for individual variation in recovery from brain injury, and will point the way towards the development of new therapeutic approaches.
The mouse is often the model of choice for genetic analysis of neurological disorders, but the introduction of disease mutations into a single inbred strain sometimes fails to yield phenotypes relevant to human disease. Interrogating genetically diverse panels of mice can identify better models of human sensitivity and resistance to candidate disease variants. We developed an in vitro methodology for modeling multiple stages of central nervous system development using a panel of genetically diverse mouse embryonic stem cell lines. Chemical knockdown of the neurodevelopmental gene Dyrk1a demonstrated profound strain differences in the cellular response to the ablation of DYRK1A activity throughout development in vitro. Responsive strains showed in vitro developmental defects consistent with observations in vivo on Dyrk1a knockout mice, and transcriptomic analysis of sensitive and resistant cell strain backgrounds successfully identified key molecular pathways in neural development known to be associated with Dyrk1a haploinsufficiency in vivo. Thus, we demonstrate that high throughput comparative phenotype analysis of differentiated cells from human and genetically diverse mouse pluripotent stem cells bearing disease mutations can provide a facile route to identification of optimal mouse strains for precision disease modeling in vivo.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.